Review Article

Efficacy of Cold Atmospheric Plasma Therapy on Chronic Wounds: An Updated Systematic Review and Meta-Analysis of RCTs

Julan Guo, Yuxing Huang, Bojun Xu, and Jiao Yang

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

Correspondence should be addressed to Bojun Xu; xubojun85@163.com and Jiao Yang; jessieyang321@163.com

Received 9 August 2022; Accepted 26 September 2022; Published 10 October 2022

Academic Editor: Liaqat Ali

Copyright © 2022 Julan Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. A previous meta-analysis has revealed that cold atmospheric plasma (CAP) might not be clinically beneficial to chronic wounds. However, several new randomized controlled trials (RCTs) reported that CAP was an effective treatment option for accelerating wound healing in chronic wounds. The purpose of this review is to incorporate these new results and evaluate the efficacy of CAP in chronic wounds.

Methods. The major databases, including PubMed, Embase, Cochrane Library, and Web of Science, were searched for articles related to CAP treatment in chronic wounds until March 21, 2022. The literature retrieval and evaluation were carried out by two independent researchers.

Results. A total of 13 randomized clinical trials published between 2010 and 2022 were finally included. CAP therapy showed to be more effective in reducing the area of wounds (mean difference (MD): -1.74, 95%; confidence interval (CI): [-3.14, -0.33], \( p = 0.02 \)), compared with non-CAP treatments. The immediate reduction of the bacterial load was higher in the CAP group than in the control group. (MD: -0.37, 95%; CI: [-0.7, -0.05], \( p = 0.02 \)).

Conclusion. No significant changes were found in long-term antibacterial efficacy and pain perception between the two groups. However, more RCTs of excellent methodological quality are required to confirm technical details of the source of AP and the appropriate duration of the treatment with plasma.

1. Introduction

Chronic wound is a serious global health issue that results in significant economic and social burdens [1, 2]. Chronic wounds are generally classified into five common types: diabetic foot ulcers, arterial ulcers, venous ulcers, pressure ulcers, and traumatic ulcers. The standard treatment for chronic wounds includes the underlying diseases management, pharmacotherapies, vascular surgery if indicated, and application of absorbent wound dressings on the ulcer lesion. Despite the aggressive therapy described above, the cure rate of chronic wounds is still unsatisfactory, and the recurrence rate is high [1]. Currently, some advanced therapies, including high-intensity laser therapy [3], platelet-rich plasma [4], and stem cell-based therapies [5] are now being tested in clinical studies to see if they might enhance wound healing.

Cold atmospheric plasma (CAP) has been demonstrated to be a potential therapy for wound healing. It refers to a physical plasma (primarily ionized gas) generated at normal atmospheric pressure and ambient temperature, which contains multiple synergistically-acting components such as charged particles, electric currents, ultraviolet radiation, and reactive gas species [6]. The use of CAP in medicine has sparked significant controversy around the world. At present, some studies have been carried out, such as CAP research on cancer [7], antibacterial effect [8], and biological safety [9]. A previously published meta-analysis [10] indicates that CAP fails to bring clinical benefits to chronic wounds healing. However, after that, several new randomized controlled trials (RCTs) have compared the healing effects of CAP on chronic wounds compared to the treatment without CAP. The results indicated that CAP can be an effective treatment option for accelerating wound healing.
in chronic wounds. The purpose of this review is to incorporate these new results and evaluate the efficacy of CAP in chronic wounds.

### 2. Methods

#### 2.1. Inclusion Criteria

The inclusion criteria were set based on the PICO principle:

- **(i) Types of Participants (P).** Patients with chronic wounds
- **(ii) Types of Intervention (I).** Cold atmospheric plasma
- **(iii) Types of control (C).** Conventional treatments for chronic wounds or placebo
- **(iv) Outcomes measures (O).** (a) Primary outcomes: (i) the reduction of the wound area; (ii) the reduction of the bacterial load; (b) the secondary outcomes: assessment of pain (visual analogue scale) and level of inflammatory cytokines.

Non-RCTs, observational studies, animal studies, case reports, literature reviews, and conference summaries were excluded.

#### 2.2. Search Strategy

The literature search was conducted by two reviewers independently. PubMed, Embase, Cochrane Library, and Web of Science databases for all related studies were published before March 21, 2022. The following search strategy was used for the PubMed database: “Wounds and Injuries [MeSH Terms]” or “wound” or “ulcer” or “injury” or “injuries” or “Trauma∗” AND “Plasma Gases [MeSH Terms]” or “atmospheric pressure glow discharge” or “atmospheric pressure plasma” or “Cold atmospheric plasma” or “Cold atmospheric pressure plasma” or “cold plasma” or “low-temperature plasma” or “non-thermal atmospheric pressure plasma” or “non-thermal dielectric barrier discharge” or “non-thermal gas plasma” or “plasma device” or “tissue tolerable plasma”. Titles and abstracts of retrieved articles were browsed, and irrelevant studies were removed. Full text of potentially eligible studies was obtained and read to identify studies to be included.

#### 2.3. Quality Assessment

Two reviewers (GL J and YX H) independently performed the quality assessment of included studies using the Cochrane Risk of Bias Assessment Tool [11], which contained the following domains: randomization sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcome assessments, incomplete data, and selective reporting. Disagreement
| Author/Year | Design | Country | Sample size (E/C) | Age (range or mean ± SD) | Type of wound | Intervention group | CAP technical parameters | Control group | Outcomes | Treatment endpoints or treatment duration |
|------------|--------|---------|------------------|--------------------------|----------------|------------------|-----------------------|----------------|----------|----------------------------------------|
| Isbary15 2010 | RCT | Germany | 38/38 | 40–94y | VU, AU, DFU, TU | 5 min of CAP every day and ST | Microwave 2.46 GHz, 86 W; Ar2.2 slm; distance to torch 2 cm | ST | ② | Negative bacterial swabs or the wound was healed, or the patient decided to stop. |
| Isbary16 2012 | RCT | Germany | α: 14/14 β: 10/10 | 40–85y | AU, VU, TU | 2 min of CAP every day and ST | Microwave 2.46 GHz; voltage 50–100 V; power 86 W; Ar2.2 slm | ST | ② | Negative bacterial swabs or the wound was healed, or the patient decided to stop. |
| Heinlin17 2013 | RCT | Germany | 34/34 | 64.8 ± 13.4y | Skin graft donor site healing | 2 min of CAP every day and ST | Microwave 2.45 GHz, 86 W; Ar2.2 slm; distance to torch 2 cm | Placebo and ST | ② | Complete healing of the donor site or the patient decided to stop. |
| Mirpour22 2020 | RCT | Tehran | 22/22 | E: 60.2 ± 5.5y C: 54.6 ± 8.8y | DFU | CAP (3 times a week for 3 weeks) and ST | Helium gas; voltage 10 kV; frequency 6 kHz | ST | ② ③ | 3 weeks |
| Moelleken19 2020 | RCT | Germany | E1: 14 E2: 13 C: 10 | E1: avg65.2y E2: avg66.8y C: avg73.7y | VU, DFU, pyoderma gangrenosum | E1: CAP (1 time a week for 12 weeks) and ST E2: CAP (3 times a week for 12 weeks) and ST | Ar | Placebo and ST | ② ③ | 12 weeks |
| Amini21 2020 | RCT | Tehran | 22/22 | 18–80y | DFU | CAP (3 times a week for 3 weeks) and ST | Helium gas; voltage 10 kV; Frequency 6 kHz | ST | ② ③ | 3 weeks |
| Samsavar23 2021 | RCT | Tehran | 10/10 | E: 62 ± 6.06y C: 59.9 ± 6.23y | DFU | CAP (2 times a week for 6 weeks) and ST | Helium gas; voltage 4.5 kV; frequency 22 kHz | ST | ② | 6 weeks |
| Author/Year | Design | Country | Sample Size (E/C) | Age (range or mean ± SD) | Type of Wound | Intervention Group | CAP Technical Parameters | Control Group | Outcomes | Treatment Duration |
|-------------|--------|---------|------------------|--------------------------|----------------|-------------------|----------------------|---------------|-----------|-------------------|
| Strohal 2022 | RCT | Austria | 39/39 | E: 42.58–93.91 y C: 42.58–93.91 y | VLU, DFU | 3 times in the 1st week, twice in the 2nd week, and once per week in the following observation period | CAP-jet treatment (kINPen® med, neoplasm GmbH, Greifswald/ Germany) | Best practice wound dressings | (b) | 6 weeks |
| Quantitative analysis | | | | | | | | | | |
| Brehmer 2014 | RCT | Germany | 7/7 | E: 51–85 y C: 51–83 y | VLU | CAP (3 times per week for 8 weeks) and ST | Frequency 50 Hz, maximum power consumption: 8 VA | ST | (b) (c) | 8 weeks |
| Chuangsawanich 2016 | RCT | Thailand | 23/19 | E: 70.75 ± 17.5 y C: 70.7 ± 1 y | PU | CAP (once per week for 8 weeks) and ST | Ar; frequency 15–20 Hz; peak voltage was around 6 to 7 kV | ST | | 8 weeks |
| Stratman 2020 | RCT | Germany | 33/32 | E: 68.3 ± 9.5 y C: 68.7 ± 8.8 y | DFU | CAP (8 times within 2 weeks) and ST | Ar | ST | | 2 weeks |
| Van Welzen 2021 | RCT | Germany | 10/10 | 74.8 ± 8.1 y | Skin graft donor site healing | CAP (3 times for 1 week) and ST | CAP was applied using a single dose of 100–240 V and 1.3–8 VA | ST | (b) | 1 week |
| Hiller 2022 | RCT | Germany | 14/13 | E: 66.2 ± 11.2 y C: 68.0 ± 8.6 y | DFU | CAP (8 times within 2 weeks) and ST | Ar | Placebo and ST | | |

Abbreviations: CAP: cold atmospheric plasma; RCT: randomized clinical trials; E-CAP group; C: control group; y-years; ST: standard treatment; Ar: argon gas; DFU: diabetic foot ulcer; VLU: venous leg ulcer; VU: venous ulcer; AU: arterial ulcer; PU: pressure ulcer; TU: traumatic ulcer. Outcomes: (a) reduction of wound area (cm²); (b) immediate reduction of the bacterial load (log Nfc/Nic, where Nfc/Nic is the number of colonies after (before) each treatment; (c) long-term reduction of the bacterial load (log Nfc/Nic, where Nfc/Nic is the number of colonies after (before) the entire treatment duration; (d) assessment of pain (visual analogue scale (VAS) from 0 (no pain) to 10 (most severe pain)); (e) the level of inflammatory cytokine.
between the two reviewers was settled via discussion and/or consultation with a third author. Review Manager (RevMan version 5.4) was applied for the risk of bias assessment.

2.4. Data Extraction. Data extracted was processed by two reviewers (GL J and YX H), independently using a predefined standardized form, which contained: name of the authors, region, sample size, age, type of wound, a description of the intervention, control groups, and outcomes. Disagreements were settled through consulting the third reviewer.

2.5. Statistical Analysis. All statistical analysis was performed using Review Manager (Ver 5.4). Risk difference (RD) and relative risk (RR) were used as pooled statistic for dichotomous data, and mean difference (MD) was used for continuous data. The 95% confidence intervals (95% CI) of each effect were provided. Heterogeneity among the included studies was assessed using $I^2$ statistics. An $I^2$ equal or greater than 50% indicated significant heterogeneity and random-effect model would be applied, otherwise (an $I^2$ less than 50%), fixed-effect model would be applied. Sensitivity analysis was conducted to assess the robustness of the results via excluding studies of high risk of bias. Funnel plot and Egger’s regression test would be applied to assess the publication bias if more than 10 studies were included. A $p$ value less than 0.05 would be considered statistically significant.

3. Results

3.1. Study Selection. Our search strategy retrieved a total of 1,619 articles, and 353 duplicated references were excluded. A total of 1266 studies were initially identified by reading the titles and abstracts. The reasons for the exclusion of the articles are shown in Figure 1. After a comprehensive review of full texts, 71 articles were excluded for the following reasons: conference abstract ($n = 19$), not satisfying inclusion criteria ($n = 39$), and nonrandomized controlled trial ($n = 15$). Finally, 8 papers were included in quantitative synthesis and 5 studies in qualitative analysis. The flow diagram of the study selection process is shown in Figure 1.

3.2. General Characteristics of the Included Studies. Characteristics of included studies are presented in Table 1. Eight studies [12–20] were conducted in Germany, three in Iran [21–23], one in Austria [24], and one in Thailand [20]. The 13 included studies involved a total of 477 participants, who were randomized either into CAP treatment group or control group. Patients in the CAP group received both CAP treatment and standard treatment in all of the studies reviewed, although CAP treatment differed significantly in each study. The most-frequently applied standard treatments included debridement, offloading treatment, and wound dressing. There was considerable variation in the type of wound, the source of CAP, and technical details of the parameters applied among the included studies.

3.3. Quality of the Included Studies. Quality assessments of included studies are shown in Figure 2. Six studies [12, 17, 20–22] reported the generation of random sequences, and three studies [12, 14, 24] reported allocation concealment. Appropriate blinding of patients was reported in only four studies [12, 14, 17, 19]. Participants in six studies [12, 14, 20–23] were unaware of the group they were assigned, and outcome assessors in four studies [12, 14, 17, 21, 22] were blind to the allocation. Since wound size measurement and bacterial load assessment would be unlikely affected by lack of blinding, the risk of performance and detection bias was considered low. Additionally, because patients who were lost to follow-up and withdrawals were reported in detail, incomplete outcome data were considered to be of low risk of bias. All included RCTs failed to neither prereport the study protocol nor register on any clinical trial registry. This led to unclear reporting bias.

3.4. Primary Outcomes

3.4.1. Reduction of Wound Area. Four trials [19, 22–24] reported the reduction of wound area (unit: cm$^2$), with 98 patients in CAP group and 91 in control group. As the
heterogeneity was detected ($I^2 = 18\%$), a fixed-effects model was used. Meta-analysis showed that CAP treatment was more effective in reducing the wound area [MD = $-1.74$, 95% CI (-3.14, -0.33), $p = 0.02$, Figure 3], compared with the control group. Sensitivity analysis showed that the removal of any single study did not reverse the results, indicating satisfactory reliability of the outcomes.

### 3.4.2. Reduction of the Bacterial Load

Three studies [15, 16, 21] reported the immediate reduction of the bacterial load

**Table 1: Immediate Reduction of the Bacterial Load**

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|--------|----------------------------------|
| Mirpour 2020      | -2.17            | 3.68 | 22    | -0.83        | 1.35 | 22    | 73.7%  | -1.34 (-2.98, 0.30)              |
| Moelleken 2020 a  | -2.63            | 11.87 | 14    | 0.1          | 3.56 | 10    | 4.5%   | -2.73 (-9.33, 3.87)              |
| Moelleken 2020 b  | -2.15            | 12.02 | 13    | 0.1          | 3.56 | 10    | 4.2%   | -8.10 (-15.00, -1.20)            |
| Samsavar 2021     | -7.71            | 10.05 | 10    | -2.04        | 7.21 | 10    | 3.4%   | -5.67 (-13.34, 2.00)             |
| Moelleken 2020 b  | -4.72            | 5.57 | 39    | -2.83        | 10.47 | 39   | 14.3%  | -0.69 (-4.41, 3.03)              |

Total (95% CI)     | 98               |       |       | 100.0%       |       |       |        | -1.74 (-3.14, -0.33)              |

Heterogeneity: $\chi^2= 4.90$, df = 4 ($P = 0.30$); $I^2=18\%$

Test for overall effect: $Z = 2.42 (P = 0.02)$

**Figure 4: (a) Immediate reduction of the bacterial load; (b) long-term reduction of the bacterial load**

**Table 2: Long-term Reduction of the Bacterial Load**

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|--------|----------------------------------|
| Amini 2020        | -0.61            | 0.92 | 22    | -0.28        | 0.94 | 22    | 46.5%  | -0.63 (-0.45, 0.51)              |
| Isbary 2010       | -1.1             | 1.53 | 38    | -0.41        | 0.98 | 38    | 31.9%  | -0.69 (-1.27, 0.11)              |
| Isbary 2012 α     | -1.15            | 1.19 | 14    | -0.26        | 0.97 | 14    | 16.5%  | -0.89 (-1.69, -0.09)             |
| Isbary 2012 β     | -1.1             | 1.93 | 10    | -0.69        | 1.29 | 10    | 5.1%   | -0.41 (-1.85, 1.03)              |

Total (95% CI)     | 84               |       |       | 100.0%       |       |       |        | -0.37 (-0.70, -0.05)             |

Heterogeneity: $\chi^2= 5.47$, df = 3 ($P = 0.14$); $I^2=45\%$

Test for overall effect: $Z = 2.42 (P = 0.02)$

**Figure 3: Reduction of wound area.**

**Figure 5: Assessment of pain (VAS).**
The heterogeneity was statistically significant using the visual analogue scale (VAS), which could score 3.4.

3.4.3. Assessment of Pain. Two studies [17, 19] assessed wound pain of patients before and at the end of treatment using the visual analogue scale (VAS), which could score the pain for 0 (no fall of pain) to 10 (most severe pain). As the heterogeneity was statistically significant ($I^2 = 78\%$), a random-effect model was used. The pooled results showed no statistically significant difference between the two groups (MD: $1.86, 95\% CI: [-5.36, 9.08], p = 0.61$).

4. Discussion

A previous meta-analysis [10] concluded that CAP treatment did not significantly improve wound healing. However, recently, multiple RCTs have shown that CAP can promote the wound healing. The pooled results revealed that CAP was more effective in accelerating wound healing in chronic wounds compared to the control group. Two main study outcomes were focused in our study: the ability of CAP reducing the area of wounds and the bacterial load in wounds.

Results of quantitative synthesis demonstrated that CAP could be an efficient method to reduce the immediate bacterial load in the wound. Previous studies [25] reported that CAP could generate reactive nitrogen species (RNS) and reactive oxygen species (ROS), which directly affected microorganisms and might cause their inactivation. Reactive nitrogen substances can accumulate on the surface of microorganisms and easily diffuse through cell membranes, resulting in a decrease in intracellular pH. Intracellular pH is important for cell function due to its influences in enzyme activity, reaction rate, protein stability, and nucleic acid structure. Xu et al. [26] reported that helium CAP could reduce staphylococcal biofilm by more than 5 orders of magnitude in only 5 minutes of treatment, indicating that CAP had a short-term antisepsic effect, which was consistent with the results of our results.

A study by Brehmer et al. [18] found a significant bacterial load reduction in chronic venous ulcers in leg following the application of CAP, while no evident reduction was observed in ulcer bacterial strain numbers after an 8-week plasma treatment. Likewise, the results of our quantitative analysis revealed that the antibacterial effects did not seem to last long. Stratmann et al. [12] found that at the end of the treatment, the microbial load was reduced in both CAP and placebo treatment groups without significant difference, suggesting that CAP had no long-term antibacterial efficacy.

Another major outcome of this review was the reduction of the wound area. The pooled results showed that in patients with chronic wounds, CAP was more effective in reducing wound area compared to the control group. In another randomized clinical trial [12], CAP therapy showed beneficial effects on the healing of chronic wound as demonstrated by the reduction of wound area and time to wound closure. Moreover, in an RCT [20] that recruited 50 patients with pressure ulcers, the reduction of wound area and decrease in bacterial load were scored and assessed. The wound healing in CAP treatment group showed to be more favorable, compared with control group. First of all, the efficacy of CAP in the reduction of chronic wound areas was attributed to the reduction of bacteria on the wound surface. Bacteria are the most prevalent cause of chronic inflammation that attenuates wound healing. Reactive species produced by CAP are expected to enhance wound healing by reducing bacteria on the surface of the wound [15, 16]. Amini et al. [21] also demonstrated that CAP changed the antibiotic resistance, attributed to the reduction of bacteria on the wound surface. Despite the long-term antibiotic effects did not seem to last long, Stratmann et al. [12] found that at the end of the treatment, the microbial load was reduced in both CAP and placebo treatment groups without significant difference, suggesting that CAP had no long-term antibacterial efficacy.
publication bias, considering less than 10 studies for quantitative analysis. In the future, more high-quality RCTs are necessary to evaluate the efficacy of CAP on chronic wounds.

5. Conclusion

CAP is an effective treatment for chronic wounds for its effects on reducing bacterial load and wound area, and it will be a promising treatment for chronic wounds. Future research should include the technical details of the source and application parameters of CAP, the appropriate duration of plasma treatment, and the wound characteristics that determine the best treatment.

Abbreviations

CAP: Cold atmospheric plasma  
RCTs: Randomized controlled trials  
MD: Mean difference  
Cl: Confidence interval  
RDs: Risk differences  
RRs: Relative risks  
ROS: Reactive oxygen species  
VAS: Visual analogue scale.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest to disclose.

Authors’ Contributions

All authors contributed to the study conception and design. Julan Guo and Yuxing Huang contributed equally to this work. Julan Guo and Yuxing Huang performed the conceptualization, methodology, software, writing the original draft, data curation, and visualization of the manuscript; Bojun Xu and Jiao Yang were responsible for the methodology, software, writing the original draft, conceptualization, supervision, and project administration. All authors read and approved the final manuscript.

References

[1] R. G. Frykberg and J. Banks, "Challenges in the treatment of chronic wounds," Advances in Wound Care, vol. 4, no. 9, pp. 560–582, 2015.
[2] L. Martinengo, M. Olsson, R. Bajpai et al., "Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies," Annals of Epidemiology, vol. 29, pp. 8–15, 2019.
[3] M. S. Alayat, A. M. el-Sodany, A. A. Ebid et al., "Efficacy of high intensity laser therapy in the management of foot ulcers: a systematic review," Journal of Physical Therapy Science, vol. 30, no. 10, pp. 1341–1345, 2018.
[4] W. Qu, Z. Wang, C. Hunt et al., "The effectiveness and safety of platelet-rich plasma for chronic wounds: a systematic review and meta-analysis," Mayo Clinic Proceedings, vol. 96, no. 9, pp. 2407–2417, 2021.
[5] K.-J. Chiang, L.-C. Chiu, Y.-N. Kang, and C. Chen, "Autologous stem cell therapy for chronic lower extremity wounds: a meta-analysis of randomized controlled trials," Cells, vol. 10, no. 12, p. 3307, 2021.
[6] P. C. Friedman, "Cold atmospheric pressure (physical) plasma in dermatology: where are we today?," International Journal of Dermatology, vol. 59, no. 10, pp. 1171–1184, 2020.
[7] A. Dubuc, P. Monsarrat, F. Virard et al., "Use of cold-atmospheric plasma in oncology: a concise systematic review," Therapeutic Advances in Medical Oncology, vol. 10, article 1758835918786475, 2018.
[8] I. Niedźwiedź, A. Watko, J. Pawlat, and M. Polak-Berecka, “The state of research on antimicrobial activity of cold plasma,” Polish Journal of Microbiology, vol. 68, no. 2, pp. 153–164, 2019.
[9] D. Boehm and P. Bourke, "Safety implications of plasma-induced effects in living cells - a review of in vitro and in vivo findings," Biological Chemistry, vol. 400, no. 1, pp. 3–17, 2018.
[10] O. Assadian, K. J. Ousey, G. Daeschlein et al., "Effects and safety of atmospheric low-temperature plasma on bacterial reduction in chronic wounds and wound size reduction: a systematic review and meta-analysis," International Wound Journal, vol. 16, no. 1, pp. 103–111, 2019.
[11] M. Cumpston, T. Li, M. J. Page et al., "Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions," Cochrane Database of Systematic Reviews, vol. 10, article Ed000142, Article ID 10.1002/14651858.ed000142, 2019.
[12] B. Stratmann, T. C. Costea, C. Nolte et al., "593-P: cold atmospheric plasma for accelerated wound healing in diabetic foot: the prospective, randomized, placebo-controlled KPW-trial," Diabetes, vol. 69, no. 1, 2020.
[13] A. van Welzen, M. Hoch, P. Wahl et al., "The response and tolerability of a novel cold atmospheric plasma wound dressing for the healing of split skin graft donor sites: a controlled pilot study," Skin Pharmacology and Physiology, vol. 34, no. 6, pp. 328–336, 2021.
[14] J. Hiller, B. Stratmann, J. Timm, T. C. Costea, and D. Tschoepe, "Enhanced growth factor expression in chronic diabetic wounds treated by cold atmospheric plasma," Diabetic Medicine, vol. 39, no. 6, article e14787, 2022.
[15] G. Isbary, G. Morfill, H. U. Schmidt et al., "A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients," The British Journal of Dermatology, vol. 163, no. 1, pp. 78–82, 2010.
[16] G. Isbary, J. Heinlin, T. Shimizu et al., "Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial," The British Journal of Dermatology, vol. 167, no. 2, pp. 404–410, 2012.
[17] J. Heinlin, J. L. Zimmermann, F. Zeman et al., "Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites," Wound Repair and Regeneration, vol. 21, no. 6, pp. 800–807, 2013.
[18] F. Brehmer, H. A. Haenssle, G. Daeschlein et al., "Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622)," *Journal of the European Academy of Dermatology and Venereology*, vol. 29, pp. 148–155, 2014.

[19] M. Moelleken, F. Jockenhöfer, C. Wiegand, J. Buer, S. Benson, and J. Dissemond, "Pilotstudie zum Einfluss von kaltem atmosphärischem Plasma auf bakterielle Kontamination und Heilungstendenz chronischer Wunden," *Journal der Deutschen Dermatologischen Gesellschaft*, vol. 18, no. 10, pp. 1094–1102, 2020.

[20] A. Chuangsuwanich, T. Assadamongkol, and D. Boonyawan, "The healing effect of low-temperature atmospheric-pressure plasma in pressure ulcer: a randomized controlled trial," *The International Journal of Lower Extremity Wounds*, vol. 15, no. 4, pp. 313–319, 2016.

[21] M. R. Amini, M. Sheikh Hosseini, S. Fatollah et al., "Beneficial effects of cold atmospheric plasma on inflammatory phase of diabetic foot ulcers; a randomized clinical trial," *Journal of Diabetes and Metabolic Disorders*, vol. 19, no. 2, pp. 895–905, 2020.

[22] S. Mirpour, S. Fathollah, P. Mansouri et al., "Cold atmospheric plasma as an effective method to treat diabetic foot ulcers: a randomized clinical trial," *Scientific Reports*, vol. 10, no. 1, article 10440, 2020.

[23] S. Samsavar, H. Mahmoudi, R. Shakouri et al., "The evaluation of efficacy of atmospheric pressure plasma in diabetic ulcers healing: a randomized clinical trial," *Dermatologic Therapy*, vol. 34, no. 6, article e15169, 2021.

[24] R. Strohal, S. Dietrich, M. Mittlböck, and G. Hämmerle, "Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trial," *Scientific Reports*, vol. 12, no. 1, p. 3645, 2022.

[25] P. Bourke, D. Ziuzina, L. Han, P. J. Cullen, and B. F. Gilmore, "Microbiological interactions with cold plasma," *Journal of Applied Microbiology*, vol. 123, no. 2, pp. 308–324, 2017.

[26] Z. Xu, J. Shen, Z. Zhang et al., "Inactivation effects of non-thermal atmospheric-pressure helium plasma jet on staphylococcus aureus biofilms," *Plasma Processes and Polymers*, vol. 12, no. 8, pp. 827–835, 2015.

[27] K. P. Arjunan, G. Friedman, A. Fridman, and A. M. Clyne, "Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species," *Journal of the Royal Society Interface*, vol. 9, no. 66, pp. 147–157, 2012.

[28] E. J. Peters, R. Lagrand, P. Smits et al., "Cold atmospheric pressure plasma as a novel treatment modality in diabetic foot ulcers-a pilot study," *Diabetes*, vol. 67, 2018.